| Texto completo | |
| Autor(es): |
Lucchi, Danilo B. M.
;
Sasso, Gisela R. S.
;
Sena, Leticia S.
;
Santos, Diego D.
;
Franco, Paulo C.
;
Lice, Izabella
;
Borges, Fernanda T.
;
Oliani, Sonia M.
;
Gil, Cristiane D.
Número total de Autores: 9
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Life Sciences; v. 304, p. 10-pg., 2022-09-01. |
| Resumo | |
Aims: In this study we evaluated the effect of pharmacological treatment with AnxA1-derived peptide Ac2-26 in an experimental model of toxicity induced by cisplatin. Main methods: Male rats were divided into Sham (control), Cisplatin (received intraperitoneal injections of 10 mg/kg/day of cisplatin for 3 days) and Ac2-26 (received intraperitoneal injections of 1 mg/kg/day of peptide, 15 min before cisplatin) groups. Key findings: After 6 h of the last dose of cisplatin, an acute inflammatory response was observed characterized by a marked increase in the number of neutrophils and GM-CSF, IL-beta, IL-6, IL-10 and TNF-alpha plasma levels. These findings were associated with increased AnxA1 protein levels in liver and kidneys, as well as positive AnxA1/Fpr2 circulating leukocytes. Treatment with Ac2-26 produced higher levels of GM-CSF, corroborating the high numbers of neutrophils, and the anti-inflammatory cytokine IL-4. Ac-2-(26) preserved the morphology of liver structures and increased Fpr1 expression, preventing the damage caused by cisplatin. In the kidneys, Ac2-26 caused downregulation of renal Fpr1 and Fpr2 levels and abrogated the increased levels of the CLU and KIM-1 biomarkers of kidney damage induced by cisplatin. However, no effect of peptide treatment was detected in cisplatin-induced kidney morphology injury. Significance: Despite activation of the anti-inflammatory AnxA1/Fpr axis during cisplatin administration, treatment with Ac2-26 did not efficiently prevent its deleterious effects on the liver and kidneys. (AU) | |
| Processo FAPESP: | 19/14331-5 - Efeito do peptídeo mimético da anexina A1 na toxicidade hepática e renal induzida pela cisplatina em ratos |
| Beneficiário: | Danilo Bancalero Mendonça Lucchi |
| Modalidade de apoio: | Bolsas no Brasil - Iniciação Científica |
| Processo FAPESP: | 19/19949-7 - Avaliação da atividade imunomoduladora da proteína anexina A1 em lesões cutâneas e placentárias resultantes do Diabetes Mellitus |
| Beneficiário: | Sonia Maria Oliani |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 20/03565-2 - Efeito da anexina A1 e de seus peptídeos miméticos em modelos de resposta inflamatória in vitro (2D e 3D) e de toxicidade aguda in vivo |
| Beneficiário: | Cristiane Damas Gil |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |